Orphan Drug Prices 25 Times More Expensive Than Traditional Drugs, AHIP Finds Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today following the release of a new report from America’s Health Insurance Plans (AHIP) that found Big Pharma manipulated The Orphan Drug Act in order to raise the prices of […]
In case you missed it, a recent article in HealthLeaders details how brand name drug maker Mallinckrodt used a foundation to secretly hike the price of the drug Acthar from $50 to $32,200 over a 13-year period, all while marketing the drug as ‘free’ in an illegal kickback scheme. The company used kickbacks in the […]
Americans Have Negative View of Drug Makers by Two-to-One Margin, Worst of Any Industry And the winner of this year’s most poorly regarded U.S. industry? We’ll give you a hint. It’s not oil and gas, big banks or even the federal government – it’s Big Pharma. A new poll released this morning from Gallup finds […]
Voices From Around the Country Call for Congress to Pass Senate Finance Package Americans across the country are urging Congress to hold Big Pharma accountable and lower prescription drug prices by passing The Prescription Drug Pricing Reduction Act Of 2019. This bipartisan, market-based legislative package marks an important first step towards tackling the crisis of […]
In case you missed it, a recent article in The Economist digs into the inner workings of Big Pharma-backed charities and how the industry uses them as a vehicle to boost their bottom line. These charities create the illusion that they’re helping make costly drugs more accessible for patients, but in reality Big Pharma’s generosity […]
BIO CEO Says Prescription Drugs Are Not Too Expensive If you needed any more evidence that Big Pharma is tone deaf to the growing crisis of rising prescription drug prices, look no further than a Tuesday C-SPAN interview with BIO President and CEO Jim Greenwood. During the interview, on C-SPAN’s “Washington Journal” program, Greenwood answers […]
Applauds HHS For Appealing Ruling Against List Price Transparency Measure Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement today after the U.S. Department of Health and Human services appealed a federal ruling blocking the implementation of a measure to require drug makers to disclose list prices in direct-to-consumer (DTC) advertising. […]
Analysis Finds PBMs Pass On Over 99 Percent of Rebates, Used to Keep Premiums Down A new report from the Government Accountability Office (GAO) undermines a common refrain in Big Pharma’s blame game targeting pharmacy benefit managers (PBMs) and rebates. In an effort to distract from their own price-gouging and anti-competitive behavior, Big Pharma frequently […]
Q2 Earnings: Big Pharma Keeps Living the Good Life While Evading Accountability Drug Makers Sweep Profit Forecasts as Industry Continues to Price-Gouge American Patients Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Wednesday following earnings announcements from 12 of the world’s largest brand name drug manufacturers that showed all had […]
Four More Rx Giants Complete the Sweep, Beat Q2 Earnings Forecasts After Hiking Prices Over the past week, CSRxP has been tracking Q2 earnings for the biggest prescription drug manufacturers in the world. Yesterday, four more of these Big Pharma giants – Amgen, Eli Lilly, Merck and Pfizer – completed the sweep by reporting […]